NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 26 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54 | -1.8% | 599 | 0.0% | 0.00% | – |
| Q2 2023 | $55 | -64.7% | 599 | 0.0% | 0.00% | – |
| Q1 2023 | $156 | +23.8% | 599 | 0.0% | 0.00% | – |
| Q4 2022 | $126 | – | 599 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 599 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 599 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 599 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 599 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 599 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -99.9% | 599 | 0.0% | 0.00% | – |
| Q1 2021 | $1,210,000 | +120900.0% | 599 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 599 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | 0.0% | 599 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | – | 599 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 599 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | – | 599 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 599 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Allred Capital Management, LLC | 466,688 | $41,862 | 0.02% |
| Warberg Asset Management LLC | 194,997 | $17,491 | 0.00% |
| Virtu Financial LLC | 333,069 | $30 | 0.00% |
| UBS Group AG | 149,612 | $13,466 | 0.00% |
| NewEdge Advisors, LLC | 412 | $36 | 0.00% |
| Parallel Advisors, LLC | 350 | $31 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,604 | $143 | 0.00% |
| WELLS FARGO & COMPANY/MN | 5,632 | $504 | 0.00% |
| NORTHERN TRUST CORP | 39,414 | $3,535 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |